CO2018005163A2 - Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo - Google Patents

Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo

Info

Publication number
CO2018005163A2
CO2018005163A2 CONC2018/0005163A CO2018005163A CO2018005163A2 CO 2018005163 A2 CO2018005163 A2 CO 2018005163A2 CO 2018005163 A CO2018005163 A CO 2018005163A CO 2018005163 A2 CO2018005163 A2 CO 2018005163A2
Authority
CO
Colombia
Prior art keywords
compound
triazolo
pyrimidin
compositions
pde2
Prior art date
Application number
CONC2018/0005163A
Other languages
English (en)
Inventor
Petrus Jacobus Johannes Antonius Buijnsters
Henricus Jacobus Maria Gijsen
Abdallah Ahnaou
Wilhelmus Helena Ignatius Maria Drinkenburg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2018005163A2 publication Critical patent/CO2018005163A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un nuevo derivado de [1,2,4]triazolo[1,5-a]pirimidin-ilo como inhibidor de fosfodiesterasa 2 (PDE2). La invención también se refiere a composiciones farmacéuticas que comprenden el compuesto, a procedimientos para preparar dicho compuesto y composiciones, y al uso de dicho compuesto y composiciones para la prevención y tratamiento de trastornos en los que está implicada la PDE2, tales como trastornos neurológicos y psiquiátricos.
CONC2018/0005163A 2015-11-02 2018-05-16 Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo CO2018005163A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192661 2015-11-02
EP15192966 2015-11-04
PCT/EP2016/076420 WO2017076900A1 (en) 2015-11-02 2016-11-02 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND

Publications (1)

Publication Number Publication Date
CO2018005163A2 true CO2018005163A2 (es) 2018-06-20

Family

ID=57256277

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005163A CO2018005163A2 (es) 2015-11-02 2018-05-16 Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo

Country Status (20)

Country Link
US (1) US10947239B2 (es)
EP (1) EP3371188B1 (es)
JP (1) JP6872541B2 (es)
KR (1) KR20180075630A (es)
CN (1) CN108349979B (es)
AU (1) AU2016348549B2 (es)
BR (1) BR112018008431A2 (es)
CA (1) CA3001768C (es)
CO (1) CO2018005163A2 (es)
EA (1) EA036851B1 (es)
ES (1) ES2765738T3 (es)
HK (1) HK1256751A1 (es)
IL (1) IL259004B (es)
MX (1) MX2018005342A (es)
MY (1) MY194700A (es)
PH (1) PH12018500944B1 (es)
SG (1) SG11201803605YA (es)
UA (1) UA122423C2 (es)
WO (1) WO2017076900A1 (es)
ZA (1) ZA201802842B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
US10947239B2 (en) 2015-11-02 2021-03-16 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
MX2018010301A (es) 2016-02-25 2019-05-20 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
KR20190071721A (ko) 2016-11-02 2019-06-24 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
MX2019005154A (es) * 2016-11-02 2019-06-20 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
BR112019008604A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
CA3044762A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
CN114605416B (zh) * 2020-12-08 2023-12-01 奥锐特药业(天津)有限公司 阿卡替尼晶型i的制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
AU745425B2 (en) 1998-01-27 2002-03-21 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl factor Xa inhibitors
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
DE60326742D1 (de) 2002-10-03 2009-04-30 Vertex Pharma Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten
WO2004108136A1 (en) * 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo `1 , 5-a!pyrimidines and their use in medicine
EP1781659B1 (en) 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
KR20060105872A (ko) 2003-12-29 2006-10-11 반유 세이야꾸 가부시끼가이샤 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
AU2005286731A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2007113136A1 (de) 2006-03-30 2007-10-11 Basf Aktiengesellschaft Verwendung von substituierten riazolopyrimidinen zur bekämpfung von phyto pathogenen schadpilzen
JP2007332061A (ja) 2006-06-14 2007-12-27 Nippon Kayaku Co Ltd 新規ピラゾロ[1,5−a]ピリミジン誘導体及びその用途
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2012080727A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
SG192576A1 (en) 2011-02-23 2013-09-30 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
AU2012311061B2 (en) 2011-09-23 2016-08-18 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6418950B2 (ja) 2012-03-09 2018-11-07 レクシコン ファーマシューティカルズ インコーポレイテッド ピラゾロ[1,5−a]ピリミジン系化合物、それを含む組成物、及びそれらを使用する方法
KR102313353B1 (ko) * 2013-07-29 2021-10-18 삼성전자주식회사 캐릭터 입력 방법 및 디스플레이 장치
CN106255679B (zh) 2014-02-27 2019-09-06 默克专利有限公司 用作nav通道抑制剂的杂环化合物及其用途
CN106255689B (zh) 2014-03-19 2019-09-17 勃林格殷格翰国际有限公司 杂芳基syk抑制剂
SI3597649T1 (sl) * 2014-04-23 2022-04-29 Dart Neuroscience Llc Sestavki, ki vsebujejo substituirane (1,2,4)triazolo(1,5-a)pirimidin-7-ilne spojine, kot zaviralci pde2
CN105566321B (zh) 2014-10-29 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN105753817A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 一类取代氮杂环衍生物及其应用
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
US10947239B2 (en) 2015-11-02 2021-03-16 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
WO2017157882A1 (en) 2016-03-14 2017-09-21 Université Catholique de Louvain Serine biosynthetic pathway inhibitors
BR112019008604A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
MX2019005154A (es) 2016-11-02 2019-06-20 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
KR20190071721A (ko) 2016-11-02 2019-06-24 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
CA3044762A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds

Also Published As

Publication number Publication date
SG11201803605YA (en) 2018-05-30
WO2017076900A1 (en) 2017-05-11
AU2016348549B2 (en) 2020-07-23
IL259004A (en) 2018-06-28
JP6872541B2 (ja) 2021-05-19
IL259004B (en) 2021-06-30
EA036851B1 (ru) 2020-12-28
UA122423C2 (uk) 2020-11-10
EP3371188B1 (en) 2019-10-23
ES2765738T3 (es) 2020-06-10
PH12018500944A1 (en) 2018-11-19
HK1256751A1 (zh) 2019-10-04
CN108349979B (zh) 2021-04-09
CN108349979A (zh) 2018-07-31
MX2018005342A (es) 2018-08-15
EA201891067A1 (ru) 2018-10-31
JP2018535968A (ja) 2018-12-06
ZA201802842B (en) 2021-04-28
CA3001768A1 (en) 2017-05-11
AU2016348549A1 (en) 2018-04-26
PH12018500944B1 (en) 2018-11-19
CA3001768C (en) 2022-12-13
US10947239B2 (en) 2021-03-16
US20180327408A1 (en) 2018-11-15
KR20180075630A (ko) 2018-07-04
MY194700A (en) 2022-12-15
BR112018008431A2 (pt) 2018-11-06
EP3371188A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
CO2018005163A2 (es) Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
CO6602133A2 (es) Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas
MX2019005154A (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
CO2019006858A2 (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
NI201900060A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
CR20190003A (es) 1H-PIRAZOLO[4,3-b]PIRIDINAS COMO INHIBIDORES DE PDE1
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
ECSP19043790A (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1
CO6531468A2 (es) Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10
PL3597649T3 (pl) Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
BR112019008163A2 (pt) compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
CO2018010323A2 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX2019005123A (es) Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2.
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
MX2015000336A (es) Inhibidores de la enzima fosfodiesterasa 10.